"I strongly recommend Zhongshan to all Shanghai-based enterprises present here today, especially those who want to tap into the Greater Bay Area market."

Zhang Shaodian, CEO and founder of Shanghai-based company SYNYI AI, delivered a speech at the 2024 Zhongshan Business Environment Promotion Conference on November 5 as a representative of enterprises in the Yangtze River Delta region that had settled projects in Zhongshan, volunteering as an "investment promotion ambassador" of Zhongshan.

SYNYI AI is a quasi-unicorn company in the medical field founded by overseas returned scientists. It made the list of Forbes AI 50 in China. Headquartered in Shanghai, the company entered the Greater Bay Area market five years ago.

"On June 28 this year, Guangdong SYNYI was registered, only 99 days since my first official visit to Zhongshan. And less than half a year, SYNYI AI's South China center officially opened... This all showcases the incredible 'Zhongshan speed'." Zhang Shaodian explained the reason he chose to settle the company in Zhongshan.

"From the bottom of my heart, I invite everyone to do business and pursue development in Zhongshan," said Zhang Shaodian, adding that he hopes Zhongshan will have a better future and more enterprises, especially technology-based ones, will seek development in Zhongshan.

Ma Zhenkun, founder and CEO of TenNor Therapeutics, a company that is based in Suzhou and also settles its project in Zhongshan, recommended Zhongshan during the conference as well.

TenNor Therapeutics is a company dedicated to developing first-in-class new drugs in the field of bacterial infections and bacterial metabolic diseases. On May 24 this year, TenNor Therapeutics signed an investment agreement with the Zhongshan Cuiheng Jianhui Industrial Park, planning to invest 300 million yuan in building industrial headquarters.

"I believe TenNor Therapeutics can take root and develop in Zhongshan, a fertile land for the biomedical industry, and go global in the future," said Ma Zhenkun, adding that Zhongshan attaches great importance to the biomedical industry and provides strong support in terms of policy, talent introduction and innovation environment building.